{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vie privée : Questions médicales les plus fréquentes",
"headline": "Vie privée : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vie privée : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-09",
"dateModified": "2025-03-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vie privée"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Législation comme sujet",
"url": "https://questionsmedicales.fr/mesh/D007878",
"about": {
"@type": "MedicalCondition",
"name": "Législation comme sujet",
"code": {
"@type": "MedicalCode",
"code": "D007878",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.706.615"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vie privée",
"alternateName": "Privacy",
"code": {
"@type": "MedicalCode",
"code": "D018907",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Erman Ayday",
"url": "https://questionsmedicales.fr/author/Erman%20Ayday",
"affiliation": {
"@type": "Organization",
"name": "Computer Engineering Department, Bilkent University, 06800 Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Kai-Chih Chang",
"url": "https://questionsmedicales.fr/author/Kai-Chih%20Chang",
"affiliation": {
"@type": "Organization",
"name": "Department of Electrical and Computer Engineering, The University of Texas at Austin, Austin, TX 78712, USA."
}
},
{
"@type": "Person",
"name": "Suzanne Barber",
"url": "https://questionsmedicales.fr/author/Suzanne%20Barber",
"affiliation": {
"@type": "Organization",
"name": "Department of Electrical and Computer Engineering, The University of Texas at Austin, Austin, TX 78712, USA."
}
},
{
"@type": "Person",
"name": "Yahan Yang",
"url": "https://questionsmedicales.fr/author/Yahan%20Yang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Vision Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, Guangdong."
}
},
{
"@type": "Person",
"name": "Haotian Lin",
"url": "https://questionsmedicales.fr/author/Haotian%20Lin",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Vision Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, Guangdong."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Clinically Optimal Neuropsychological Tests for Postoperative Cognitive Dysfunction in Heart Valve Surgeries.",
"datePublished": "2022-10-05",
"url": "https://questionsmedicales.fr/article/36198576",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1253/circj.CJ-22-0390"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prevalence, demographics, and cognitive dysfunction among methamphetamine-dependent individuals with childhood maltreatment.",
"datePublished": "2022-07-07",
"url": "https://questionsmedicales.fr/article/35820226",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpsychires.2022.07.018"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction: A Randomized Clinical Trial.",
"datePublished": "2024-10-01",
"url": "https://questionsmedicales.fr/article/39356507",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.36874"
}
},
{
"@type": "ScholarlyArticle",
"name": "Gut flora reflects potential risk factors for cognitive dysfunction in patients with epilepsy.",
"datePublished": "2024-09-28",
"url": "https://questionsmedicales.fr/article/39342383",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s41043-024-00639-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Task-based profiles of language impairment and their relationship to cognitive dysfunction in Parkinson's disease.",
"datePublished": "2022-10-27",
"url": "https://questionsmedicales.fr/article/36301842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0276218"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Organisations et économie des soins de santé",
"item": "https://questionsmedicales.fr/mesh/D004472"
},
{
"@type": "ListItem",
"position": 3,
"name": "Contrôle social formel",
"item": "https://questionsmedicales.fr/mesh/D012926"
},
{
"@type": "ListItem",
"position": 4,
"name": "Législation comme sujet",
"item": "https://questionsmedicales.fr/mesh/D007878"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vie privée",
"item": "https://questionsmedicales.fr/mesh/D018907"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vie privée - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vie privée",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vie privée",
"description": "Comment évaluer la vie privée d'un patient ?\nQuels outils aident à protéger la vie privée ?\nQu'est-ce qu'une violation de la vie privée ?\nComment identifier un risque pour la vie privée ?\nQuels sont les indicateurs d'une bonne protection de la vie privée ?",
"url": "https://questionsmedicales.fr/mesh/D018907?mesh_terms=Cognitive+Dysfunction&page=7#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vie privée",
"description": "Quels signes indiquent une atteinte à la vie privée ?\nComment les patients réagissent-ils aux violations ?\nQuels impacts psychologiques d'une violation ?\nLes patients signalent-ils souvent des violations ?\nQuels symptômes de méfiance chez les patients ?",
"url": "https://questionsmedicales.fr/mesh/D018907?mesh_terms=Cognitive+Dysfunction&page=7#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vie privée",
"description": "Comment prévenir les violations de la vie privée ?\nQuelles pratiques de confidentialité sont recommandées ?\nComment sensibiliser les patients à leur vie privée ?\nQuels outils technologiques aident à la prévention ?\nComment impliquer les patients dans la protection de leur vie privée ?",
"url": "https://questionsmedicales.fr/mesh/D018907?mesh_terms=Cognitive+Dysfunction&page=7#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vie privée",
"description": "Comment traiter une violation de la vie privée ?\nQuelles lois protègent la vie privée des patients ?\nComment former le personnel à la vie privée ?\nQuels protocoles pour protéger la vie privée ?\nComment évaluer l'efficacité des mesures de protection ?",
"url": "https://questionsmedicales.fr/mesh/D018907?mesh_terms=Cognitive+Dysfunction&page=7#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vie privée",
"description": "Quelles conséquences d'une violation de la vie privée ?\nComment une violation affecte-t-elle la réputation d'un établissement ?\nQuels impacts sur la relation patient-médecin ?\nQuelles sanctions pour les violations de la vie privée ?\nComment gérer les conséquences psychologiques d'une violation ?",
"url": "https://questionsmedicales.fr/mesh/D018907?mesh_terms=Cognitive+Dysfunction&page=7#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vie privée",
"description": "Quels facteurs augmentent le risque de violation ?\nComment la technologie influence-t-elle la vie privée ?\nQuels comportements des employés sont risqués ?\nComment les politiques de l'établissement influencent-elles la vie privée ?\nQuel rôle joue la sensibilisation à la sécurité ?",
"url": "https://questionsmedicales.fr/mesh/D018907?mesh_terms=Cognitive+Dysfunction&page=7#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la vie privée d'un patient ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer la vie privée implique d'examiner les pratiques de collecte et de stockage des données."
}
},
{
"@type": "Question",
"name": "Quels outils aident à protéger la vie privée ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des outils comme les logiciels de cryptage et les systèmes de gestion des accès sont essentiels."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une violation de la vie privée ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une violation se produit lorsque des informations personnelles sont divulguées sans consentement."
}
},
{
"@type": "Question",
"name": "Comment identifier un risque pour la vie privée ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Identifier les risques nécessite une analyse des processus de gestion des données personnelles."
}
},
{
"@type": "Question",
"name": "Quels sont les indicateurs d'une bonne protection de la vie privée ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des politiques claires, des formations régulières et des audits fréquents sont des indicateurs clés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une atteinte à la vie privée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent des fuites d'informations, des plaintes de patients ou des audits échoués."
}
},
{
"@type": "Question",
"name": "Comment les patients réagissent-ils aux violations ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent ressentir de l'anxiété, de la méfiance ou même changer de praticien."
}
},
{
"@type": "Question",
"name": "Quels impacts psychologiques d'une violation ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les violations peuvent entraîner stress, dépression et sentiment d'insécurité chez les patients."
}
},
{
"@type": "Question",
"name": "Les patients signalent-ils souvent des violations ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, beaucoup de violations ne sont pas signalées par crainte de représailles ou de stigmatisation."
}
},
{
"@type": "Question",
"name": "Quels symptômes de méfiance chez les patients ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent poser plus de questions ou hésiter à partager des informations sensibles."
}
},
{
"@type": "Question",
"name": "Comment prévenir les violations de la vie privée ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des technologies de sécurité, former le personnel et établir des politiques claires."
}
},
{
"@type": "Question",
"name": "Quelles pratiques de confidentialité sont recommandées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Limiter l'accès aux données, anonymiser les informations et obtenir le consentement éclairé."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser les patients à leur vie privée ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer les patients sur leurs droits et les pratiques de protection des données est essentiel."
}
},
{
"@type": "Question",
"name": "Quels outils technologiques aident à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des outils comme les VPN, le chiffrement et les systèmes de gestion des accès sont utiles."
}
},
{
"@type": "Question",
"name": "Comment impliquer les patients dans la protection de leur vie privée ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Encourager les patients à poser des questions et à exprimer leurs préoccupations est crucial."
}
},
{
"@type": "Question",
"name": "Comment traiter une violation de la vie privée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il faut informer les patients, évaluer les dommages et renforcer les mesures de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles lois protègent la vie privée des patients ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des lois comme le RGPD en Europe et HIPAA aux États-Unis protègent les données personnelles."
}
},
{
"@type": "Question",
"name": "Comment former le personnel à la vie privée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des formations régulières sur la confidentialité et la sécurité des données sont essentielles."
}
},
{
"@type": "Question",
"name": "Quels protocoles pour protéger la vie privée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Mettre en place des protocoles de consentement, de stockage et de partage des données est crucial."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des mesures de protection ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des audits réguliers et des évaluations de conformité aident à mesurer l'efficacité des mesures."
}
},
{
"@type": "Question",
"name": "Quelles conséquences d'une violation de la vie privée ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences incluent des poursuites judiciaires, des amendes et une perte de confiance."
}
},
{
"@type": "Question",
"name": "Comment une violation affecte-t-elle la réputation d'un établissement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une violation peut gravement nuire à la réputation, entraînant une perte de patients et de revenus."
}
},
{
"@type": "Question",
"name": "Quels impacts sur la relation patient-médecin ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les violations peuvent créer de la méfiance, rendant la communication et le traitement plus difficiles."
}
},
{
"@type": "Question",
"name": "Quelles sanctions pour les violations de la vie privée ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les sanctions peuvent inclure des amendes, des poursuites et des mesures disciplinaires internes."
}
},
{
"@type": "Question",
"name": "Comment gérer les conséquences psychologiques d'une violation ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Offrir un soutien psychologique et des ressources d'accompagnement est essentiel pour les patients."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de violation ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme le manque de formation, des systèmes obsolètes et des politiques floues augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment la technologie influence-t-elle la vie privée ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation accrue des technologies numériques peut accroître les risques de violations de données."
}
},
{
"@type": "Question",
"name": "Quels comportements des employés sont risqués ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des comportements comme le partage d'identifiants ou l'accès non autorisé aux données sont risqués."
}
},
{
"@type": "Question",
"name": "Comment les politiques de l'établissement influencent-elles la vie privée ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des politiques claires et strictes aident à protéger la vie privée, tandis que des politiques laxistes l'exposent."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la sensibilisation à la sécurité ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La sensibilisation à la sécurité aide à réduire les comportements à risque et à protéger les données."
}
}
]
}
]
}
Postoperative cognitive dysfunction (POCD) is widely recognized and reported, but the lack of a uniform definition makes it difficult to evaluate its clinical impact. The aim of this study is to estab...
MoCA was the only neuropsychological test that predicted the clinical impact on complex events and has the potential to define POCD....
Previous studies have shown that dependent individuals (DIs) have higher rates of childhood maltreatment and poorer cognitive performance compared with healthy controls. However, little attention has ...
Neurologic post-COVID-19 condition (PCC), or long COVID, symptoms of fatigue and cognitive dysfunction continue to affect millions of people who have been infected with SARS-CoV-2. There currently are...
To assess the effects of lithium aspartate therapy on PCC fatigue and cognitive dysfunction....
A randomized, double-blind, placebo-controlled trial (RCT) enrolling participants in a neurology clinic from November 28, 2022, to June 29, 2023, with 3 weeks of follow-up, was conducted. Subsequently...
Lithium aspartate, 10 to 15 mg/d, or identically appearing placebo for 3 weeks followed by open-label lithium aspartate, 10 to 15 mg/d, for 2 weeks. In the subsequent dose-finding study, open-label li...
Change in sum of FSS-7 and BFSS scores. The scores for each measure range from 7 to 49, with higher scores indicating more severe symptoms. Secondary outcomes included changes from baseline in the sco...
Fifty-two participants were enrolled (30 [58%] males; mean [SD] age, 58.54 [14.34] years) and 26 were randomized to treatment with lithium aspartate (10 females) and 26 to placebo (12 female). Two par...
In this RCT, therapy with lithium aspartate, 10 to 15 mg/d, was ineffective for neurologic PCC fatigue and cognitive dysfunction. Another RCT is required to assess the potential benefits of higher lit...
ClinicalTrials.gov Identifier: NCT05618587 and NCT06108297....
This cross-sectional study aims to analyze the differences in gut flora between patients with epilepsy with and without cognitive impairment and normal subjects....
One hundred patients with epilepsy who came to our hospital from 2020.12 to 2022.12 (epilepsy group) were selected, and another 100 family members of the patients were selected as the control group (c...
There were more significant differences in the structure and composition of the gut flora between patients in the epilepsy group and the control group, but no significant differences in diversity anal...
There was an imbalance in the gut flora of patients with epilepsy compared to healthy controls. The gut flora of patients with epilepsy with cognitive dysfunction differs significantly from that of pa...
Parkinson's Disease (PD) is associated with both motor and non-motor problems, such as cognitive impairment. Particular focus in this area has been on the relationship between language impairment and ...
22 non-demented people with PD (PwPD) and 22 healthy control participants performed a range of cognitive and language tasks. Cognitive tasks included a screening assessment in addition to tests for se...
The study highlighted impaired ability in set-shifting and letter fluency in the executive function tasks, and a higher rate of grammatical and lexical errors across all language tasks in the PD group...
Our results suggest that there is a link between executive function and language performance, but that this is task dependent in non-demented PwPD. This has implications for the management of language...
Sleep disturbance and cancer-related cognitive impairment (CRCI) are two of the most common symptoms reported by patients undergoing chemotherapy. Less is known about how these symptoms co-occur and t...
A total of 1,333 oncology outpatients receiving chemotherapy completed self-report questionnaires on sleep disturbance and cognitive dysfunction six times over two cycles of chemotherapy. Latent profi...
Two distinct profiles were identified (i.e., Low = low levels of both sleep disturbance and cognitive dysfunction (53.5%); High = high levels of both sleep disturbance and cognitive dysfunction (45.5%...
Almost half of the patients undergoing chemotherapy experienced clinically meaningful levels of both symptoms. Of note, sleep disturbance is frequently overlooked by both clinicians and patients. Clin...
In children, obstructive sleep apnea (OSA) can cause cognitive dysfunctions. Amyloid-beta and tau are elevated in OSA. Neurofilament light (NfL) is a marker of neuro-axonal damage, but there are no re...
This retrospective case-control study included children diagnosed with adenoid tonsil hypertrophy from July 2017 to September 2019 at the Second Affiliated Hospital of Xi'an Jiaotong University. Corre...
Fifty-six OSA and 49 non-OSA children were included. The serum NfL levels were higher in the OSA group (31.68 (27.29-36.07) pg/ml) than in the non-OSA group (19.13 (17.32-20.95) pg/ml) (P < 0.001). Mo...
Serum NfL levels are associated with the severity of cognitive dysfunctions in children diagnosed with adenoid tonsil hypertrophy and might be a candidate noninvasive, objective marker to identify cog...
Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and Neurofilament light chain (NfL) are associated with Lewy body formation, Lewy bodies are the main pathological feature of Parkinson's disease (PD)....
There were significant differences in UCH-L1 and NfL levels among PD patients with normal cognitive function (PD-CN), PD patients with mild cognitive impairment (PD-MCI), and PD-dementia patients (PDD...
Decreased UCH-L1 levels and elevated NfL levels in the blood are associated with cognitive dysfunction in PD; thus, these proteins are potential biomarkers for the diagnosis of cognitive dysfunction i...
We aimed to develop objective criteria for cognitive dysfunction associated with the post-COVID syndrome....
Four hundred and four patients with post-COVID syndrome from two centers were evaluated with comprehensive neuropsychological batteries. The International Classification for Cognitive Disorders in Epi...
According to the developed criteria, 41.2% and 17.3% of the sample were classified as having at least one cognitive domain impaired using -1 and -1.5 standard deviations as cutoff points. Attention/pr...
We propose a harmonization of the criteria to define and classify cognitive impairment in the post-COVID syndrome. These criteria may be extrapolated to other neuropsychological batteries and settings...
Several factors could affect the cognitive dysfunction in patients with type 1 diabetes (T1D)....
To report the characteristic of cognitive dysfunction in T1D and find its association with the retinal thickness....
We recruited one hundred and seven patients with T1D in our study....
Detailed clinical and demographic factors and Cambridge Automated Neuropsychological Test Battery (CANTAB) were performed in all participants. The age at onset>5 years old and ≤5 years old groups was ...
The median age of T1D was 24.9 years old and 57 participants were women. The median age at onset was 7.4 years old, and mean disease duration was 17.2 years. After adjusting off multiple covariates by...
Our results suggest that age at onset and glycemic control had significant impacts on different cognitive domains in T1D. The CRT had a significant correlation with sustained attention, which could be...